Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd acquired 12,000 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock was bought at an average price of $1.71 per share, with a total value of $20,520.00. Following the acquisition, the director now directly owns 12,000 shares of the company’s stock, valued at $20,520. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vigil Neuroscience Stock Up 0.6 %

VIGL stock opened at $1.66 on Friday. The firm has a market cap of $67.86 million, a PE ratio of -0.81 and a beta of 1.65. The business has a 50 day moving average of $3.05 and a 200-day moving average of $3.50. Vigil Neuroscience, Inc. has a 12-month low of $1.60 and a 12-month high of $6.06.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on VIGL shares. William Blair initiated coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, Wedbush increased their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $19.75.

Institutional Trading of Vigil Neuroscience

A number of institutional investors have recently modified their holdings of VIGL. Acadian Asset Management LLC purchased a new position in Vigil Neuroscience during the second quarter worth about $26,000. Renaissance Technologies LLC increased its holdings in shares of Vigil Neuroscience by 19.2% in the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vigil Neuroscience in the second quarter valued at approximately $87,000. Geode Capital Management LLC boosted its position in Vigil Neuroscience by 41.9% during the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after buying an additional 66,712 shares during the period. Finally, Walleye Capital LLC grew its stake in shares of Vigil Neuroscience by 334.4% in the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.